2022
Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF
Murray EM, Greene SJ, Rao VN, Sun JL, Alhanti BA, Blumer V, Butler J, Ahmad T, Mentz RJ. Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF. American Heart Journal 2022, 254: 112-121. PMID: 36007566, DOI: 10.1016/j.ahj.2022.08.009.Peer-Reviewed Original ResearchMeSH KeywordsAtrial FibrillationClinical Trials as TopicFemaleHeart FailureHumansMachine LearningMaleObesityPrognosisStroke VolumeConceptsASCEND-HF trialAtrial fibrillationBlood pressureEjection fractionHeart failureLatent class analysisOutcomes of patientsLong-term outcomesYoung menFour-hour urine outputDistinct phenotypesAcute HFRenal impairmentClinical profileUrine outputASCEND-HFClinical benefitHeterogenous diseaseClinical dataOlder womenHFpEFPatientsOlder individualsCluster 3Asian women
2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchMeSH KeywordsAgedClinical Trials as TopicCohort StudiesDisease ProgressionFemaleHeart FailureHeart-Assist DevicesHumansIncidenceMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomesConduct of Clinical Trials in the Era of COVID-19 JACC Scientific Expert Panel
Psotka MA, Abraham WT, Fiuzat M, Filippatos G, Lindenfeld J, Ahmad T, Bhatt AS, Carson PE, Cleland JGF, Felker GM, Januzzi JL, Kitzman DW, Leifer ES, Lewis EF, McMurray JJV, Mentz RJ, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Vardeny O, Whellan DJ, Wittes J, Anker SD, O'Connor CM. Conduct of Clinical Trials in the Era of COVID-19 JACC Scientific Expert Panel. Journal Of The American College Of Cardiology 2020, 76: 2368-2378. PMID: 33183511, PMCID: PMC7836888, DOI: 10.1016/j.jacc.2020.09.544.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCoronavirus InfectionsCOVID-19Endpoint DeterminationHumansPandemicsPneumonia, ViralSocioeconomic FactorsStatistics as TopicConceptsAcademic Research ConsortiumClinical trialsExpert consensus recommendationsResearch ConsortiumScientific Expert PanelHeart failureCardiovascular diseaseConsensus recommendationsClinical careDrug AdministrationCoronavirus diseaseU.S. FoodExpert panelNational InstituteTrialsCOVID-19 pandemicDiseaseAcademic investigatorsHeartKey recommendationsSeries of meetingsPandemicPatientsAdministrationCare
2015
Use of outcome measures in pulmonary hypertension clinical trials
Parikh KS, Rajagopal S, Arges K, Ahmad T, Sivak J, Kaul P, Shah SH, Tapson V, Velazquez EJ, Douglas PS, Samad Z. Use of outcome measures in pulmonary hypertension clinical trials. American Heart Journal 2015, 170: 419-429.e3. PMID: 26385024, DOI: 10.1016/j.ahj.2015.06.010.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicHemodynamicsHumansHypertension, PulmonaryOutcome Assessment, Health CareConceptsHypertension clinical trialsPulmonary arterial hypertensionPAH trialsClinical practiceInvasive hemodynamicsPrimary endpointClinical trialsOutcome measuresInvasive measuresSurrogate measureDuke University Medical CenterPatient-centered endpointsSecondary outcome measuresClinical treatment trialsMEDLINE/EMBASEUniversity Medical CenterSmall patient populationQuality of lifeContemporary clinical practicePAH therapyPH medicationsArterial hypertensionSerial echocardiographyPatient characteristicsSecondary outcomes
2013
Therapeutic Implications of Biomarkers in Chronic Heart Failure
Ahmad T, O'Connor C. Therapeutic Implications of Biomarkers in Chronic Heart Failure. Clinical Pharmacology & Therapeutics 2013, 94: 468-479. PMID: 23856627, DOI: 10.1038/clpt.2013.139.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, PharmacologicalChronic DiseaseClinical Trials as TopicHeart FailureHumansModels, CardiovascularNatriuretic PeptidesConceptsChronic heart failureHeart failureTherapeutic implicationsBiomarker-guided clinical trialsTreatment of HFPotential therapeutic implicationsClinical trial designImportant therapeutic implicationsUse of biomarkersHemodynamic disordersClinical trialsClinical careTrial designTherapeutic potentialBiomarker studiesMolecular biomarkersBiomarkersMolecular dysfunctionMolecular pathwaysDysfunctionFailurePathophysiologySyndromeTrialsCare